Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Friday, October 18, 2024
The perioperative use of the anti–PD-1/VEGF bispecific antibody ivonescimab, with or without chemotherapy, was the focus of a phase II trial in resectable non–small cell lung cancer (NSCLC). At the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract OA01.06), Xiaoliang Zhao, MD, of Tianjin Medical University Cancer Institute & Hospital, China, reported that the use of ivonescimab, both as monotherapy and in combination with chemotherapy, yielded high rates of major pathologic response and pathologic complete response. Better outcomes were seen with the combination in patients with squamous NSCLC than in those with nonsquamous NSCLC, and the treatment resulted in no treatment-related adverse events that interfered with surgery.
This open-label, multicenter phase II trial enrolled 60 patients with resectable stage II to IIIB (N2) NSCLC. Participants were assigned to one of two cohorts: cohort 1 received neoadjuvant ivonescimab monotherapy (20 mg/kg), and cohort 2 received ivonescimab (20 mg/kg or 30 mg/kg) combined with cisplatin/carboplatin and paclitaxel. Patients underwent 3 or 4 cycles of treatment every 3 weeks before surgery, followed by up to 16 cycles of adjuvant ivonescimab.
In cohort 1, 10 patients completed surgery, with 60% achieving a major pathologic response and 30% reaching a pathologic complete response. In cohort 2, 39 patients completed surgery, with higher rates of major pathologic response (71.8%) and pathologic complete response (43.6%). Of note, patients with squamous NSCLC had major pathologic response and pathologic complete response rates of 83.3% and 53.3%, respectively. Ivonescimab at 30 mg/kg plus chemotherapy produced better responses than did the 20-mg/kg dose.
The treatment was reported to be well tolerated, with the most common treatment-related adverse events being decreased neutrophil and white blood cell counts. No treatment-related adverse events led to a delay or cancellation of surgery.
Disclosure: For full disclosure information, visit wclc2024.iaslc.org.
2024 World Conference on Lung Cancer
JNCCN Spotlights
